COVID-19 Total Solutions
Antibody diagnosis COV03
PCL COVID19 IgG/IgM Rapid Gold
Diagnostic kit
| use |
· Antibody diagnostic kit that detects IgG and IgM antibodies for the diagnosis of COVID-19 infection in human capillary blood
|
|---|---|
| Performance Summary |
· 10-minute qualitative detection of COVID-19 IgG/IgM antibody
· No analyzer required
· IgG : detection limit - 1:20000
· IgM : detection limit - 1:10000
· Clinical sensitivity: 91.06% (112/123, after seroconversion*)
· Clinical specificity: 99.37% (1104/1111, after seroconversion *)
|
| How to use: Specimen collection through capillary blood |
|---|
|
|
| Certification and Supply countries |
|---|
|
• CE Certificate
• Australia TGA
• Russia Federation
• India / Greece
• Bolivia
• MFDS (KFDA)
• FIND Listed
• UNGM Supplier
Exporting to more than 40 countries
|
| Recommended No. 1 in korea - PCL COVID19 Antibody kit |
|---|
|
Recommended products by Korean doctors to WHO
PCL Rapid Antibody Diagnostic Kit shows equivalent or better performance to products of other companies that have received Emergency Use Authorization (EUA) in the evaluation of the US FDA.
The world's best performing diagnostic kit (provided by Seoul C University Hospital)
It was mentioned that the sensitivity of the PCL antibody diagnostic kit was 92.9% and the specificity was 96.2%.
*Performance paper of immunodiagnostic kit for rapid detection of IgM and IgG in 2019 coronavirus disease published by users of top university hospitals
|
Comparison with products from other companies that have received EUA
As a result of the US FDA evaluation, PCL rapid diagnostic kits all proved excellent performance in sensitivity, specificity, PPV, NPV, and etc (refer to the yellow-green bar shown in the graph above).
Comparison with products of other companies that have applied for EUA
As a result of the US FDA evaluation, PCL rapid diagnostic kits demonstrated excellent performance in sensitivity, specificity, PPV, and NPV (refer to the graph above).